Inflammation targeted nanomedicines: Patents and applications in cancer therapy

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery

Background:

• Inflammation plays a key role in cancer development and progression, leading to the use of anti-inflammatory drugs as a therapeutic strategy.
• Targeted delivery of anti-inflammatory agents to cancerous cells remains a significant challenge for conventional therapies.
• Nanotechnology presents a promising avenue for developing safe and effective targeted cancer therapies.

Purpose of the Study:

• To review the strategies, progress, successes, and challenges in developing anti-inflammatory nanotherapeutics for cancer.
• To highlight patented innovations in anti-inflammatory nanomedicines and their role in clinical translation.
• To identify obstacles hindering the successful clinical translation of anti-inflammatory nanomedicines.

Main Methods:

• Comprehensive literature review of anti-inflammatory nanomedicines in cancer therapy.
• Analysis of patented innovations and their impact on therapeutic development.
• Introspection into the challenges and future perspectives of nanomedicine translation.

Main Results:

• Nanotechnology offers potential for targeted delivery of anti-inflammatory drugs, overcoming limitations of conventional methods.
• Patents are crucial for protecting innovations and facilitating the transition from laboratory research to clinical application.
• Complexities of cancer, incomplete understanding of nanomedicine behavior in vivo, and production scalability impede nanomedicine development.

Conclusions:

• A thorough understanding of strategies, progress, and challenges is essential for shifting towards anti-inflammatory nanotherapeutics.
• Addressing the identified glitches is critical for the successful clinical translation of anti-inflammatory nanomedicines.
• Further research and development, supported by robust patent strategies, are needed to realize the full potential of nanomedicines in cancer treatment.